ACKNOWLEDGMENTS
The authors would like to thank Patricia Hughes and Kalavati Suvarna, both from FDA, for helpful discussions regarding this
article.
ANASTASIA G. LOLAS (not pictured) is president of Visionary Pharma Consulting, Olney, MD, and ANURAG S. RATHORE, PHD*, is a consultant at Biotech CMC Issues and a member of the faculty in the department of chemical engineering at the Indian
Institute of Technology. Rathore is also a member of BioPharm International's Editorial Advisory Board.
*To whom correspondence should be addressed, asrathore@biotechcmz.com
.
REFERENCES
1. J. Arrowsmith, Nature Biotechnol. 11, 17–18 (2012).
2. FDA, Notice of Pilot Program for Submission of Quality Information for Biotechnology Products in the Office of Biotechnology
Products, Docket number FDA-2008-N-03551.
3. FDA, Pharmaceutical CGMPs for the 21st Century - A Risk-Based Approach, Final Report (Rockville, MD, Sept. 2004).
4. J.M. Juran, Juran on Quality by Design, (The Free Press, 1992).
5. ICH Q8(R1) Pharmaceutical Development (2008).
6. FDA, Guidance for Industry, PAT—A Framework for Innovative Pharmaceutical Development, Manufacturing and Quality Assurance (Rockville, MD, Sept. 2004).
7. ICH, Q9 Quality Risk Management (2005).
8. ICH, Q10 Pharmaceutical Quality System (2008).
9. FDA, Guidance for Industry, Process Validation: General Principles and Practices (Rockville, MD, 2011).
10. A.S. Rathore and H. Winkle, Nature Biotechnol. 27, 26–34 (2009).
11. A.S. Rathore Trends in Biotechnol. 27, 546–553 (2009).
12. S. Kozlowski and P. Swann (2009) "Considerations for Biotechnology Product Quality by Design," In: A.S. Rathore and R.
Mhatre (eds) Quality by Design for biopharmaceuticals: Perspectives and Case Studies, (Wiley Inter-science, New Jersey, 2009), pp. 9–30.
13. FDA, "Drug and Biological Product Consolidation," Fed. Regist. 68 (123), June 2003.
14. FDA, Center for Drug Evaluation and Research Manual of Policies and Procedures, MAPP 4730.3, Office of Biotechnology Products
and Office of ComplianceDivision of Manufacturing & Product Quality Interactions on BLA Assessments,
http://www.fda.gov/downloads/AboutFDA/CentersOffices/CDER/ManualofPoliciesProcedures/UCM195932.pdf.
15. FDA, Inspections of Licensed Biological Therapeutic Drug Products, Compliance Program Guidance Manual, Program 7356.002M,
2006,
http://www.fda.gov/downloads/ICECI/ComplianceManuals/ComplianceProgramManual/ucm125422.pdf
16. Code of Federal Regulations, Title 21, Food and Drugs (Government Printing Office, Washington, DC), Part 601.12.
17. FDA, Guidance for Industry, Guidance for Industry: Changes to an Approved Application for Specified Biotechnology and Specified
Synthetic Biological Products (Rockville, MD, July 1997).
18. ICH, Q5E Comparability of Biotechnological/ Biological Products Subject to Changes in Their Manufacturing Process (2003).
|
